Compare Stocks: AVXL, JANX, SVRA, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.23 +1.2%	$19.12	$9.54 ▼ $24.27	$1.03B	0.78	1.14 million shs	633,218 shs
AVXL Anavex Life Sciences	$2.86 +0.4%	$2.86	$2.26 ▼ $10.40	$265.12M	1.14	1.27 million shs	307,127 shs
JANX Janux Therapeutics	$20.24 +2.2%	$16.48	$12.12 ▼ $35.34	$1.24B	2.53	1.11 million shs	700,767 shs
SVRA Savara	$5.37	$5.65	$3.34 ▼ $7.01	$1.10B	0.25	1.61 million shs	625,207 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-1.76%	-5.24%	+2.54%	+45.04%	+79.92%
AVXL Anavex Life Sciences	-1.38%	-8.95%	-9.52%	+10.89%	-70.03%
JANX Janux Therapeutics	+0.51%	+5.43%	+24.06%	+48.20%	-14.06%
SVRA Savara	-1.65%	-2.19%	-0.74%	+5.50%	+57.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.23 +1.2%	$19.12	$9.54 ▼ $24.27	$1.03B	0.78	1.14 million shs	633,218 shs
AVXL Anavex Life Sciences	$2.86 +0.4%	$2.86	$2.26 ▼ $10.40	$265.12M	1.14	1.27 million shs	307,127 shs
JANX Janux Therapeutics	$20.24 +2.2%	$16.48	$12.12 ▼ $35.34	$1.24B	2.53	1.11 million shs	700,767 shs
SVRA Savara	$5.37	$5.65	$3.34 ▼ $7.01	$1.10B	0.25	1.61 million shs	625,207 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-1.76%	-5.24%	+2.54%	+45.04%	+79.92%
AVXL Anavex Life Sciences	-1.38%	-8.95%	-9.52%	+10.89%	-70.03%
JANX Janux Therapeutics	+0.51%	+5.43%	+24.06%	+48.20%	-14.06%
SVRA Savara	-1.65%	-2.19%	-0.74%	+5.50%	+57.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	134.53% Upside
AVXL Anavex Life Sciences	2.40	Hold	$21.33	645.92% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	80.15% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	88.88% Upside

Current Analyst Ratings Breakdown

Latest AVXL, JANX, SVRA, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
7/24/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	AVTX Avalo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	17,188.42	N/A	N/A	$8.37 per share	2.30
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.21 per share	N/A
JANX Janux Therapeutics	$10M	123.75	N/A	N/A	$15.18 per share	1.33
SVRA Savara	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
AVXL Anavex Life Sciences	-$46.38M	-$0.15	N/A	N/A	N/A	N/A	-11.43%	-10.72%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest AVXL, JANX, SVRA, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.08	$0.08	+$0.16	$0.08	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
7/30/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
AVXL Anavex Life Sciences	N/A	15.62	20.87
JANX Janux Therapeutics	N/A	16.35	16.35
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
AVXL Anavex Life Sciences	31.55%
JANX Janux Therapeutics	75.39%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
AVXL Anavex Life Sciences	11.40%
JANX Janux Therapeutics	7.90%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
AVXL Anavex Life Sciences	40	92.70 million	82.13 million	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
SVRA Savara	20	205.46 million	194.57 million	Optionable

AVXL, JANX, SVRA, and AVTX Headlines

Recent News About These Companies

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3 at 3:44 AM | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Analysts Set Savara Inc. (NASDAQ:SVRA) PT at $10.14

August 27, 2026 | americanbankingnews.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

August 13, 2026 | marketbeat.com

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

August 13, 2026 | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2026 | marketbeat.com

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, JANX, SVRA, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$19.23 +0.23 (+1.21%)

As of 04:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Anavex Life Sciences NASDAQ:AVXL

$2.86 +0.01 (+0.35%)

As of 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Janux Therapeutics NASDAQ:JANX

$20.24 +0.44 (+2.22%)

As of 04:00 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Savara NASDAQ:SVRA

$5.37 0.00 (0.00%)

As of 04:00 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, JANX, SVRA, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, JANX, SVRA, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, JANX, SVRA, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, JANX, SVRA, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Anavex Life Sciences NASDAQ:AVXL

Janux Therapeutics NASDAQ:JANX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, JANX, SVRA, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, JANX, SVRA, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, JANX, SVRA, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, JANX, SVRA, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Anavex Life Sciences NASDAQ:AVXL

Janux Therapeutics NASDAQ:JANX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools